Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 monotherapy and combination therapy in advanced hepatocellular carcinoma
CTR20263236Phase 2Active
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404, ipilimumab in hepatocellular carcinoma (HCC), sponsored by Pfizer. Started Sep 2026; status: active.
02
Drugs
PF-08634404ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20263236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263236.